An Industry Perspective on the 2017 EMA Guideline on First-in-Human and Early Clinical Trials.
Clin Pharmacol Ther
; 103(4): 566-569, 2018 04.
Article
en En
| MEDLINE
| ID: mdl-29285748
ABSTRACT
The European Medicines Agency (EMA) in 2017 issued a revised guideline on nonclinical and clinical aspects of first-in-human (FIH) and early clinical trials (CTs). External input was solicited during a draft comment phase, and although some industry suggestions were adopted, others were not. We agree that subject safety is of utmost priority, and believe that minimizing risk must be balanced with efficient and informative study designs to bring new medicines to patients.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ensayos Clínicos como Asunto
/
Guías como Asunto
/
Experimentación Humana Terapéutica
/
Control de Medicamentos y Narcóticos
/
Industria Farmacéutica
/
Desarrollo de Medicamentos
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Clin Pharmacol Ther
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos